An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Comirnaty (Pfizer-BioNTech COVID-19 Vaccine)

Chemical NameCOVID-19 Vaccine, mRNA
Dosage FormInjection (intramuscular; 0.3 mL)
Drug ClassVaccines
SystemRespiratory
CompanyPfizer-BioNTech
Approval Year2021

Indication

  • Indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older
Last updated on 3/28/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Pfizer-BioNTech COVID-19 (BNT162b2) Vaccine (SARS-CoV-2 vaccine) Prescribing Information.2021Pfizer Inc., New York, NY; BioNTech Manufacturing GmbH, Mainz, Germany
Document TitleYearSource
Assessment report: comirnaty. 2021EMA
Document TitleYearSource
Lymphadenopathy post-COVID-19 vaccination with increased FDG uptake may be falsely attributed to oncological disorders: a systematic review.2022Journal of Medical Virology
Evaluation of the safety profile of COVID-19 vaccines: a rapid review. 2021BMC Medicine
Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis. 2021Allergy, Asthma & Clinical Immunology
Effectiveness of COVID-19 vaccines against Delta (B.1.617.2) variant: a systematic review and meta-analysis of clinical studies. 2021Vaccines
mRNA Covid-19 vaccines in pregnancy: a systematic review. 2021PLoS One